查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1577004

快速诊断市场、机会、成长动力、产业趋势分析与预测，2024-2032

Rapid Diagnostics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球快速诊断市场估值为 227 亿美元，在早期疾病检测需求不断增长和慢性病患病率上升的推动下，2024 年至 2032 年复合年增长率将达到 9.2%。随着医疗保健转向主动式管理和早期干预，对快速、准确的诊断工具的需求变得更加重要。糖尿病和心血管疾病等慢性病的激增增加了对高效且易于使用的诊断解决方案的需求。对及时检测和有效管理的综合需求将显着扩大市场规模。

快速诊断产业根据购买、配销通路、产品、技术/平台、最终用途和地区而分散。

由于传染病检测在控制疾病爆发和管理公共卫生方面发挥关键作用，因此到 2023 年，其市场份额将达到 25.6%。随着全球感染人数的增加以及对即时、准确结果的需求，传染病的快速诊断检测变得越来越重要。测试技术的创新和早期检测意识的提高进一步推动了该领域的成长。随着对及时有效的诊断解决方案的需求持续增长，传染病检测将引领市场。

2023 年，OTC 检测领域的销售额为 149 亿美元，这归因于其便利性以及消费者对家庭健康管理日益增长的偏好。非处方药测试为各种健康状况提供即时、方便的解决方案，无需医疗保健提供者就诊。对个人化医疗保健和自我监测的日益关注，加上用户友好的测试技术的进步，正在推动这一领域的扩张。随着对易于使用且高效的诊断工具的需求增加，OTC 测试将主导市场。

北美快速诊断市场规模在2023 年达到113 亿美元，在其先进的医疗基础设施、对创新诊断解决方案的高需求以及对医疗技术的大量投资的推动下，到2032 年将以8.2% 的复合年成长率增长。该地区对早期疾病检测和个人化医疗保健的关注推动了快速诊断测试的采用。此外，强有力的医疗政策和慢性病的高发生率也有助于市场成长。北美完善的医疗保健系统和技术进步使其成为快速诊断行业的显着贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 传染病病率增加
      • 技术进步
      • 快速诊断测试日益普及
      • 人们对早期诊断的认识不断提高
      • 增加政府在传染病诊断上的倡议
    • 产业陷阱与挑战
      • 结果准确度低
      • 替代产品的可用性
      • 严格的监管框架
  • 成长潜力分析
  • 报销场景
  • 监管环境
    • 我们
    • 欧洲
  • 技术景观
  • 新兴疗法
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 传染病检测
    • 呼吸道感染检测产品
    • 流感
    • 肝炎
    • 爱滋病
    • 其他传染病测试
  • 血糖监测
  • 心臟代谢测试
  • 凝血检测产品
  • 怀孕和生育力测试
  • 肿瘤/癌症标记检测产品
  • 尿液分析检测产品
  • 胆固醇检测产品
  • 血液学检测产品
  • 滥用药物 (DoA) 检测产品
  • 粪便隐匿性检测产品
  • 其他产品

第 6 章：市场估计与预测：按购买方式，2021 - 2032 年

  • 主要趋势
  • 场外交易
  • 基于处方的测试

第 7 章：市场估计与预测：按技术/平台划分，2021 - 2032

  • 流通式
  • 固相
  • 侧流
  • 凝集试验
  • 其他技术

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

  • 医院药房
  • 砖块和灰浆
  • 电子商务
  • 其他分销管道

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 诊断中心
  • 家庭护理设置
  • 医院和诊所
  • 其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 11 章：公司简介

  • Abbott Laboratories
  • ACON Laboratories Inc.
  • Alfa Scientific Designs Inc.
  • Artron Laboratories Inc.
  • Becton, Dickinson and Company
  • BioMerieux
  • Bio-Rad Laboratories
  • Danaher Corporation (HemoCue and Radiometer)
  • Hologic
  • McKesson Medical-Surgical, Inc.
  • Meridian Bioscience, Inc.
  • QIAGEN NV
  • Quidel Corporation
  • F. Hoffmann-La Roche Ltd.
  • Sight Diagnostics Ltd.
  • Trinity Biotech
简介目录
Product Code: 5745

The Global Rapid Diagnostics Market was valued at USD 22.7 billion in 2023 and will expand to a 9.2% CAGR from 2024 to 2032, propelled by the increasing demand for early disease detection and the rising prevalence of chronic diseases. As healthcare shifts towards proactive management and early intervention, the need for quick, accurate diagnostic tools becomes more critical. The surge in chronic conditions, such as diabetes and cardiovascular diseases, amplifies the demand for efficient and accessible diagnostic solutions. This combined demand for timely detection and effective management will significantly boost the market's size.

The rapid diagnostics industry is fragmented based on purchase, distribution channel, product, technology/platform, end use , and region.

The infectious disease testing segment achieved a 25.6% share in 2023 due to its critical role in controlling disease outbreaks and managing public health. With the rise in global infections and the need for immediate, accurate results, rapid diagnostic tests for infectious diseases are increasingly essential. Innovations in testing technology and heightened awareness of early detection further drive this segment's growth. As the demand for timely and efficient diagnostic solutions continues, infectious disease testing will lead the market.

The OTC testing segment held USD 14.9 billion in 2023, attributed to its convenience and growing consumer preference for at-home health management. OTC tests offer immediate, accessible solutions for various health conditions without the need for a healthcare provider visit. The increasing focus on personalized healthcare and self-monitoring, coupled with advancements in user-friendly testing technologies, is driving the expansion of this segment. As demand for accessible and efficient diagnostic tools rises, OTC testing will dominate the market.

North America rapid diagnostics market size was exhibited at USD 11.3 billion in 2023 and will grow at an 8.2% CAGR through 2032, driven by its advanced healthcare infrastructure, high demand for innovative diagnostic solutions, and substantial investments in medical technology. The region's focus on early disease detection and personalized healthcare drives the adoption of rapid diagnostic tests. Additionally, strong healthcare policies and a high rate of chronic disease contribute to market growth. North America's well-established healthcare system and technological advancements make it a notable contributor to the rapid diagnostics industry.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of infectious disease
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Increasing popularity of rapid diagnostic tests
      • 3.2.1.4 Rising awareness regarding early diagnosis among people
      • 3.2.1.5 Increasing government initiatives for the diagnosis of infectious diseases
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Low accuracy of results
      • 3.2.2.2 Availability of substitute products
      • 3.2.2.3 Stringent regulatory framework
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
    • 3.5.1 U.S.
    • 3.5.2 Europe
  • 3.6 Technological landscape
  • 3.7 New emerging therapies
  • 3.8 GAP analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Infectious disease testing
    • 5.2.1 Respiratory infection testing products
    • 5.2.2 Influenza
    • 5.2.3 Hepatitis
    • 5.2.4 HIV
    • 5.2.5 Other infectious disease tests
  • 5.3 Glucose monitoring
  • 5.4 Cardiometabolic testing
  • 5.5 Coagulation testing products
  • 5.6 Pregnancy and fertility testing
  • 5.7 Tumor/Cancer marker testing products
  • 5.8 Urinalysis testing products
  • 5.9 Cholesterol testing products
  • 5.10 Hematology testing products
  • 5.11 Drug-of-abuse (DoA) testing products
  • 5.12 Fecal occult testing products
  • 5.13 Other products

Chapter 6 Market Estimates and Forecast, By Purchase, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 OTC
  • 6.3 Prescription-based tests

Chapter 7 Market Estimates and Forecast, By Technology/Platform, 2021 - 2032 ($ Mn)

  • 7.1 Flow-through
  • 7.2 Solid phase
  • 7.3 Lateral flow
  • 7.4 Agglutination assays
  • 7.5 Other technologies

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Hospital pharmacies
  • 8.2 Brick and mortar
  • 8.3 E-commerce
  • 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 9.1 Diagnostic centers
  • 9.2 Homecare settings
  • 9.3 Hospitals and clinics
  • 9.4 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
    • 10.5.4 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Abbott Laboratories
  • 11.2 ACON Laboratories Inc.
  • 11.3 Alfa Scientific Designs Inc.
  • 11.4 Artron Laboratories Inc.
  • 11.5 Becton, Dickinson and Company
  • 11.6 BioMerieux
  • 11.7 Bio-Rad Laboratories
  • 11.8 Danaher Corporation (HemoCue and Radiometer)
  • 11.9 Hologic
  • 11.10 McKesson Medical-Surgical, Inc.
  • 11.11 Meridian Bioscience, Inc.
  • 11.12 QIAGEN N.V.
  • 11.13 Quidel Corporation
  • 11.14 F. Hoffmann-La Roche Ltd.
  • 11.15 Sight Diagnostics Ltd.
  • 11.16 Trinity Biotech